Boston Historical Balance Sheet
0HOY Stock | 90.59 0.59 0.65% |
Trend analysis of Boston Scientific Corp balance sheet accounts such as Other Current Liab of 2.8 B, Total Current Liabilities of 4.1 B or Total Stockholder Equity of 12 B provides information on Boston Scientific's total assets, liabilities, and equity, which is the actual value of Boston Scientific Corp to its prevalent stockholders. By breaking down trends over time using Boston Scientific balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Boston Scientific Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Boston Scientific Corp is a good buy for the upcoming year.
Boston Scientific Inventory |
|
Boston |
About Boston Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Boston Scientific Corp at a specified time, usually calculated after every quarter, six months, or one year. Boston Scientific Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Boston Scientific and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Boston currently owns. An asset can also be divided into two categories, current and non-current.
Boston Scientific Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Boston Scientific assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Boston Scientific Corp books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Boston Scientific balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Boston Scientific Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most accounts from Boston Scientific's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Boston Scientific Corp current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Boston Scientific's Short Term Investments are comparatively stable compared to the past year. Short Term Debt is likely to gain to about 711.3 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 2.8 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 2.7B | 2.4B | 3.2B | 2.8B | Total Assets | 32.2B | 32.5B | 35.1B | 26.4B |
Boston Scientific balance sheet Correlations
Click cells to compare fundamentals
Boston Scientific Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Boston Scientific balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 30.6B | 30.8B | 32.2B | 32.5B | 35.1B | 26.4B | |
Other Current Liab | 2.4B | 2.8B | 2.7B | 2.4B | 3.2B | 2.8B | |
Total Current Liabilities | 4.9B | 3.7B | 4.3B | 3.8B | 4.9B | 4.1B | |
Total Stockholder Equity | 13.9B | 15.3B | 16.6B | 17.6B | 19.3B | 12.0B | |
Property Plant And Equipment Net | 2.4B | 2.5B | 2.7B | 2.8B | 3.3B | 2.3B | |
Net Debt | 9.8B | 7.7B | 7.4B | 8.2B | 8.7B | 6.5B | |
Retained Earnings | (2.3B) | (2.4B) | (1.4B) | (750M) | 819M | 860.0M | |
Accounts Payable | 542M | 513M | 794M | 862M | 942M | 543.4M | |
Cash | 563M | 1.9B | 2.1B | 1.1B | 865M | 927.8M | |
Non Current Assets Total | 25.9B | 24.1B | 25.9B | 26.7B | 28.6B | 21.4B | |
Non Currrent Assets Other | 144M | 166M | 225M | 442M | 4.5B | 4.7B | |
Other Assets | 4.6B | 4.5B | 4.6B | 4.6B | 5.3B | 5.5B | |
Cash And Short Term Investments | 563M | 1.9B | 2.1B | 1.1B | 865M | 928.1M | |
Net Receivables | 1.8B | 1.5B | 1.8B | 2.0B | 2.2B | 1.7B | |
Good Will | 10.2B | 10.0B | 12.0B | 12.9B | 14.4B | 9.6B | |
Common Stock Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.4B | 1.5B | 1.5B | |
Non Current Liabilities Total | 11.8B | 11.8B | 11.3B | 11.1B | 10.7B | 9.8B | |
Inventory | 1.6B | 1.4B | 1.6B | 1.9B | 2.5B | 1.5B | |
Other Current Assets | 1.3B | 2.3B | 1.2B | 1.3B | 937M | 1.2B | |
Other Stockholder Equity | 15.8B | 17.5B | 17.7B | 18.0B | 18.4B | 17.8B | |
Total Liab | 16.7B | 15.5B | 15.6B | 14.9B | 15.6B | 14.4B | |
Total Current Assets | 4.7B | 6.7B | 6.3B | 5.8B | 6.5B | 5.0B | |
Intangible Assets | 8.2B | 6.1B | 6.2B | 6.0B | 6.0B | 6.8B | |
Short Long Term Debt Total | 10.4B | 9.6B | 9.5B | 9.3B | 9.6B | 8.1B | |
Liabilities And Stockholders Equity | 30.6B | 30.8B | 32.2B | 32.5B | 35.1B | 27.1B | |
Accumulated Other Comprehensive Income | 270M | 207M | 263M | 268M | 50M | 47.5M | |
Short Term Debt | 1.5B | 83M | 332M | 81M | 607M | 711.3M | |
Long Term Debt | 3.8B | 4.8B | 8.6B | 9.1B | 10.5B | 7.0B | |
Capital Surpluse | 17.2B | 17.3B | 17.6B | 19.7B | 22.7B | 19.5B | |
Property Plant Equipment | 2.4B | 2.5B | 2.7B | 2.8B | 3.3B | 2.4B | |
Other Liab | 3.0B | 2.2B | 2.1B | 1.8B | 1.6B | 1.9B | |
Net Tangible Assets | (4.5B) | (760M) | (1.6B) | (1.3B) | (1.5B) | (1.6B) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.